RTI-121

RTI-121 is an investigational drug that has been studied as a potential treatment for certain neurological disorders, particularly related to cognitive impairment and related conditions. It acts as a selective modulator of the mGluR2 receptor, which is part of the metabotropic glutamate receptor family. Research into RTI-121 has primarily focused on its effects in the context of treating conditions like schizophrenia and other disorders characterized by cognitive deficits.